Peptides and Banned Substances in Sports: WADA List, Testing, and TUE Process

For competitive athletes, the legal question about peptides is separate from—and in some ways more immediately consequential than—the pharmaceutical regulatory question. A peptide can be legally obtained with a prescription but still result in a multi-year competitive ban if used by an athlete subject to anti-doping rules. This guide covers the WADA prohibited list, which peptides are banned, detection methods, and the Therapeutic Use Exemption process.

WADA, USADA, and How Anti-Doping Rules Work

The World Anti-Doping Agency (WADA) publishes the Prohibited List—a document updated annually that specifies which substances and methods are banned in sport. WADA does not conduct testing directly; that is done by national anti-doping organizations (NADOs) and international federation anti-doping units.

In the United States, the US Anti-Doping Agency (USADA) implements WADA rules for Olympic, Paralympic, and Pan American sports, as well as for most major US professional sports through individual agreements. USADA conducts both in-competition and out-of-competition testing.

Athletes who compete in WADA-code compliant sports are subject to strict liability: if a prohibited substance is found in your sample, you committed an anti-doping rule violation regardless of whether you intended to use it, knew it was prohibited, or obtained it legally via prescription. Intent and circumstances affect the sanction but not the finding.

The WADA Prohibited List: Relevant Peptide Categories

The WADA Prohibited List organizes prohibited substances into sections. Several sections are directly relevant to peptides:

S1 – Anabolic Agents

This section primarily covers anabolic steroids but also includes substances with anabolic properties. Some peptides with significant anabolic activity can fall under the catch-all language in S1 covering "other substances with a similar chemical structure or similar biological effect(s)."

S2 – Peptide Hormones, Growth Factors, Related Substances, and Mimetics

This is the primary section for most research peptides. S2 explicitly prohibits:

Erythropoiesis-stimulating agents (ESAs): EPO and related peptides that stimulate red blood cell production.

Peptide hormones and releasing factors: This subcategory explicitly names:

• Growth Hormone (GH) and Growth Hormone Secretagogues (GHS)
• Insulin-like Growth Factor (IGF-1) and its analogs
• Hepatocyte Growth Factor (HGF)
• Mechano Growth Factor (MGF)
• Platelet-Derived Growth Factor (PDGF)
• Vascular Endothelial Growth Factor (VEGF)
• Fibroblast Growth Factor (FGF)
• Any other growth factor affecting muscle, tendon, ligament, bone, or cartilage

Critically, the S2 prohibition on GHS applies to all growth hormone secretagogues—meaning every GHRP (GHRP-2, GHRP-6, Hexarelin, ipamorelin) and every GHRH analog (sermorelin, CJC-1295, tesamorelin, Mod-GRF 1-29) is explicitly prohibited both in and out of competition.

S4 – Hormone and Metabolic Modulators

This section covers compounds that modulate hormones and metabolism. It explicitly prohibits:

• SARMs (for comparison)
• Myostatin inhibitors
• PPAR agonists
• Insulin and insulin mimetics

S5 – Diuretics and Masking Agents

Some peptides used for water retention management fall here.

M2 – Chemical and Physical Manipulation

Manipulation of blood samples, which may include some biological agent methods, falls under prohibited methods.

Specific Peptides and Their WADA Status

BPC-157: Added to the WADA Prohibited List in 2023 under S2 as a "growth factor affecting muscle, tendon, or ligament." This was a significant development for athletes using BPC-157 for injury rehabilitation. As of 2026, BPC-157 is explicitly prohibited both in and out of competition for athletes subject to WADA rules.

TB-500 (Thymosin Beta-4): Prohibited under S2 as a growth factor affecting muscle, tendon, ligament, bone, or cartilage. Has been explicitly prohibited for multiple years.

Ipamorelin: Prohibited under S2 as a growth hormone secretagogue. In and out of competition.

CJC-1295, Sermorelin, GHRP-2, GHRP-6, Hexarelin: All prohibited under S2 as GHS or GHRH analogs. In and out of competition.

Thymosin alpha-1: As of the 2025–2026 WADA list, thymosin alpha-1 is not explicitly named on the prohibited list. Athletes should verify current list status before assuming any compound is permitted, but thymosin alpha-1 has not been on the WADA list historically.

PT-141 (Bremelanotide): Not currently on the WADA Prohibited List. FDA-approved for sexual dysfunction.

GHK-Cu (Copper peptide): Not currently on the WADA Prohibited List. Used topically for skin applications; no demonstrated performance-enhancing mechanism in sport.

Epithalon/Epitalon: Not currently named on the WADA list. Some regulatory uncertainty given its biological activity.

GLP-1 agonists (semaglutide, liraglutide): Not currently on the WADA Prohibited List. These are prescription medications for diabetes and obesity; WADA has not (as of 2026) added them to the prohibited list despite discussion about their potential performance implications.

IGF-1: Explicitly prohibited under S2 at all times.

MGF (Mechano Growth Factor): Explicitly prohibited under S2.

Follistatin and related myostatin inhibitors: Prohibited under S4 as myostatin inhibitors.

WADA Testing Methods for Peptides

Detection of peptide doping is more technically challenging than detection of small-molecule drugs. Peptides:

• Are present in plasma at nanogram-per-milliliter concentrations
• Have short half-lives (hours to days for most)
• Are structurally similar to endogenous peptides
• Degrade rapidly in samples

WADA-accredited laboratories use several approaches:

Liquid chromatography-tandem mass spectrometry (LC-MS/MS): The gold standard for direct detection of synthetic peptides. Can detect the synthetic peptide itself or characteristic fragments. Detection windows are generally short—hours to a few days for most peptides post-use.

Immunoassays: Faster and less expensive than LC-MS/MS; used for screening. Less specific; follow-up LC-MS/MS confirmation required for adverse analytical findings.

GH Biomarker Test: A method that detects the pattern of GH isoforms in circulation—a signature that differs between exogenous GH administration and the natural GH pulse pattern. Also captures some aspects of GH secretagogue use, since the GH released by secretagogues has a different isoform profile than natural GH in some protocols.

Indirect biomarker approaches: Elevated IGF-1, IGFBP-3, and ALS in combination suggest GH axis manipulation. These serve as triggering signals for more targeted testing.

The detection window for most injectable research peptides is typically 24–72 hours post-administration using direct LC-MS/MS methods. Some peptides with longer-acting modifications (like CJC-1295 with DAC, which has a half-life of 6–8 days) have longer detection windows.

Dietary Supplements and Peptide Contamination

Athletes who purchase sports supplements should be aware that contamination with prohibited peptides has been detected in products not labeled as containing them. This is most common in products marketed for muscle growth, performance, or recovery. Third-party certification programs (NSF Certified for Sport, Informed Sport, Informed Choice) test products for prohibited substances and provide a degree of assurance that supplements comply with anti-doping standards.

The World Anti-Doping Code's strict liability provision means that supplement contamination is not a defense to an anti-doping rule violation, though it may reduce the sanction if the athlete can demonstrate the contamination was the source and exercise appropriate caution.

The Therapeutic Use Exemption (TUE) Process

An athlete who has a legitimate medical need for a prohibited substance can apply for a Therapeutic Use Exemption (TUE). The TUE process, governed by the WADA TUE criteria (ISTUE Code), requires:

1. The athlete has a diagnosed medical condition requiring treatment with a prohibited substance
2. The prohibited substance is the only reasonable treatment (no permitted alternative exists)
3. The treatment does not confer a performance advantage beyond restoring normal health
4. The condition is not a consequence of prior doping

Practical implications for peptides: TUEs are routinely granted for testosterone (for documented hypogonadism), insulin (for Type 1 diabetes), and some GH prescriptions (for documented GH deficiency). TUEs for research peptides like BPC-157 or ipamorelin are far less established—the documented medical need and lack of permitted alternatives must be demonstrated, which is harder for compounds with limited clinical evidence bases.

How to apply: Contact your national anti-doping organization (USADA in the US) or sports federation. A retroactive TUE can be granted in emergency situations, but advance applications are required for prohibited substances used out of competition.

Advice for Competing Athletes

If you compete in any sport governed by WADA rules, or in US professional sports with USADA agreements:

1. Assume that S2 prohibits everything that affects the GH/IGF-1 axis—all GHRPs, all GHRH analogs, BPC-157, TB-500, MGF, and explicitly named growth factors.
2. Verify the current prohibited list at wada-ama.org before starting any peptide protocol. The list updates annually (January 1) with mid-year amendments possible.
3. Use the WADA Prohibited List search function to check specific compounds by name and chemical class.
4. Contact USADA's Drug Reference Online (DRO) at usada.org/substances/drug-reference for specific guidance on any compound you are unsure about.
5. Third-party supplement certification does not cover injectable research peptides.

Frequently Asked Questions

Q: Is BPC-157 banned in sport? Yes. BPC-157 was added to the WADA Prohibited List under S2 (growth factors) in 2023 and remains prohibited in and out of competition for athletes subject to WADA rules as of 2026.

Q: Are collagen peptides banned in sport? No. Dietary collagen peptides (hydrolyzed collagen used as a food supplement) are not prohibited under the WADA Prohibited List. These are distinct from pharmacological research peptides.

Q: If I have a prescription for a peptide, can I use it in competition? A valid prescription establishes legal possession and procurement but does not override WADA anti-doping rules. A TUE application is the correct process for obtaining permission to use a prohibited substance for a legitimate medical reason. Strict liability means the presence of a prohibited substance in your sample is an anti-doping rule violation even with a valid prescription, unless you have a TUE.

Q: How long do peptides stay detectable? Most injectable research peptides have detection windows of 24–72 hours using current LC-MS/MS methods. Longer-acting modifications (CJC-1295 with DAC, pegylated compounds) may extend detection windows. Indirect biomarkers (IGF-1, GH isoform ratios) may remain abnormal longer than direct peptide detection windows, particularly with frequent use.

Q: Are GLP-1 agonists like Ozempic banned in sports? GLP-1 receptor agonists (semaglutide, liraglutide, etc.) are not currently on the WADA Prohibited List as of 2026. WADA has been evaluating whether these compounds provide a competitive advantage, and their status may change in future prohibited list updates.

Related Articles

• Are Peptides Legal? Complete US and International Guide
• Peptides WADA Banned List
• Best Peptides for Athletes
• Peptide Therapy for Athletes 2026
• Peptides Legal Status in the US

Track your training and recovery protocols in Optimize.